Shang-Chiun Lee, MD
Clinical Cardiac Electrophysiology · Springfield, MONPI 1588754402
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (41.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Boston Scientific at 58.5% of the total. Reporting peaked in 2020 at $29,289 and has fallen 97.0% since, to $879 in 2025.
Across 414 payments — averaging $120.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$29K
- Medtronic$8K
- Abbott$6K
- Biotronik Inc.$5K
- Impulse Dynamics (USA) Inc.$329
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$264
- plus $773 from 19 others
Across 75 payments — averaging $4270.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$261K
- Livanova USA, Inc.$29K
- Biotronik Inc.$20K
- Boston Scientific$9K
- Medtronic$2K
What the payments were for
- Speaking & faculty fees$16,10032%
- Travel & lodging$20,69141%
- Food & beverage$13,20426%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 45 | $29,264 |
| Medtronic(2 entities) | 131 | $8,293 |
| Abbott | 102 | $6,309 |
| Biotronik Inc. | 95 | $4,762 |
| Impulse Dynamics (USA) Inc. | 3 | $329 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $264 |
| Atricure, Inc. | 2 | $132 |
| ZOLL Respicardia, Inc. | 1 | $115 |
| Cordis US CORP. | 1 | $72 |
| Abiomed | 2 | $70 |
| Kestra Medical Technology Services, Inc. | 3 | $65 |
| Pfizer | 2 | $49 |
| Biobeat USA Inc. | 1 | $35 |
| Cardiovascular Systems Inc. | 2 | $32 |
| Boehringer Ingelheim | 2 | $30 |
| Irhythm Technologies, Inc. | 1 | $26 |
| Altathera Pharmaceuticals LLC | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Amgen | 1 | $19 |
| Edwards Lifesciences | 1 | $16 |
| Novartis | 1 | $12 |
| Penumbra, Inc. | 1 | $11 |
| Cvrx, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$16,259
- LOTUS EDGE$11,967
- AVEIR$3,363
- LINQ II$2,138
- Micra$1,692
- Reveal LINQ$1,211
- Rivacor 7 DR-T$895
- Edora 8 DR-T$895
- OPTIMIZER$556
- Farapulse$237
- NA$223
- Confirm Rx$220
- AURORA EV-ICD MRI SURESCAN$175
- Assurity Pacemaker$173
- ENSITE PRECISION$165
- COBALT DR MRI SURESCAN$142
- Amplia MRI$118
- remede System$115
- ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2)$111
- ATRICLIP LAA EXCLUSION SYSTEM$111
How this compares
$49,995 in reported general payments places this provider in the 85th percentile of 74 clinical cardiac electrophysiology providers in Missouri.
See all clinical cardiac electrophysiology providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 876 | $756,313 |
| XareltoRivaroxaban | 324 | $326,525 |
| EntrestoSacubitril/Valsartan | 212 | $197,635 |
| Repatha SureclickEvolocumab | 19 | $17,253 |
| Flecainide Acetate | 430 | $14,232 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 57 | $13,400 |
| Propafenone Hcl | 271 | $13,153 |
| Mexiletine Hcl | 50 | $8,822 |
| Metoprolol Succinate | 533 | $4,838 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 191 | $4,648 |
| Amiodarone Hcl | 173 | $3,951 |
| Diltiazem Hcl | 127 | $3,817 |
| Midodrine Hcl | 61 | $2,849 |
| SotalolSotalol Hcl | 176 | $2,716 |
| Warfarin Sodium | 405 | $2,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $49 | $756,313876 claims |
| Johnson & JohnsonXarelto | $20 | $326,525324 claims |
| NovartisEntresto | $12 | $197,635212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 74 clinical cardiac electrophysiology providers in Missouri.
Other clinical cardiac electrophysiology in Springfield
- Sunthosh ParvathaneniSpringfield$43K
- John GarnerSpringfield$35K
- Kamal CheemaSpringfield$30K
- Indrajeet MahataSpringfield$24K
- Jian Liang TanSpringfield$13K
- Scott FerreiraSpringfield$6K
- Stanley WigginsSpringfield$5K
- Phillip CuculichSaint Louis$473K
- Sanjaya GuptaKansas City$316K
- Daniel CooperSaint Louis$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.